EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe(GlaxoSmithKline (United Kingdom)), Heidi M. Ott(GlaxoSmithKline (United Kingdom)), Gopinath Ganji(GlaxoSmithKline (United States)), Susan Korenchuk(GlaxoSmithKline (United States)), Christine Thompson(GlaxoSmithKline (United States)), Glenn S. Van Aller(GlaxoSmithKline (United States)), Yan Liu(GlaxoSmithKline (United States)), Alan P. Graves(GlaxoSmithKline (United Kingdom)), Anthony Della Pietra(GlaxoSmithKline (United States)), Elsie Diaz(GlaxoSmithKline (United Kingdom)), Louis V. LaFrance(GlaxoSmithKline (United States)), Mark Mellinger(GlaxoSmithKline (United States)), Céline Duquenne(GlaxoSmithKline (United Kingdom)), Xinrong Tian(GlaxoSmithKline (United Kingdom)), Ryan G. Kruger(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United Kingdom)), Martín Brandt(GlaxoSmithKline (United States)), William H. Miller(GlaxoSmithKline (United Kingdom)), Dashyant Dhanak(GlaxoSmithKline (United Kingdom)), Sharad K. Verma(GlaxoSmithKline (United Kingdom)), Peter J. Tummino(GlaxoSmithKline (United Kingdom)), Caretha L. Creasy(GlaxoSmithKline (United Kingdom))
Cited by 1,787
Abstract
Related Papers
No related papers found
Powered by citation graph analysis